Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PAD2 antibody
- Development stage
- Preclinical
- Lead developer
- Pharma Foods International
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral, Intravenous, Intra-arterial, Subcutaneous, Intramuscular, Intraperitoneal, Intranasal, Oral, Rectal
01
Overview
Anti-PAD2 antibody is a preclinical monoclonal antibody developed by Pharma Foods International using its proprietary ALAgene® platform, which generates avian-derived antibodies. The therapeutic candidate targets peptidylarginine deiminase 2 (PAD2), an enzyme that catalyzes the conversion of arginine residues to citrulline. This citrullination process is a key driver in the pathogenesis of various autoimmune diseases, particularly rheumatoid arthritis, where citrullinated proteins act as neoantigens that trigger an autoimmune response. By neutralizing PAD2, the antibody aims to reduce the production of these autoantigens and mitigate the underlying inflammatory process in autoimmune conditions.
- Other names
- 抗PAD2抗体anti-peptidylarginine deiminase 2 antibody
02
Targets
PADI2 (Peptidyl arginine deiminase 2)
Beyond the preview
Go deeper on anti-PAD2 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PAD2 antibody.